Published in Proc Natl Acad Sci U S A on May 01, 1989
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol (1990) 7.27
Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1996) 5.94
Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A (1998) 4.94
Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49
Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A (1992) 3.72
Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci U S A (1995) 3.53
Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest (1994) 3.49
NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci U S A (1990) 3.28
Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A (1991) 3.22
Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest (1991) 3.00
Biomechanical forces promote embryonic haematopoiesis. Nature (2009) 2.99
The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol (2006) 2.70
Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol (1989) 2.68
Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol (2006) 2.61
Regional and cardiac haemodynamic effects of NG-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br J Pharmacol (1990) 2.58
Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation. Br J Pharmacol (1989) 2.44
Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci U S A (1991) 2.39
Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest (1998) 2.39
L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest (1992) 2.35
Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol (1993) 2.32
Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest (1992) 2.26
Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg (1991) 2.24
Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest (1992) 2.22
Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest (1992) 2.14
Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation (2014) 2.11
Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc Natl Acad Sci U S A (1993) 2.10
The effects of oxidative stress on female reproduction: a review. Reprod Biol Endocrinol (2012) 2.09
Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol (2001) 1.97
7-Nitro indazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure. Br J Pharmacol (1993) 1.97
Systemic hypertension in two patients with ASL deficiency: a result of nitric oxide deficiency? Mol Genet Metab (2009) 1.96
Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci U S A (1993) 1.96
Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc Natl Acad Sci U S A (1999) 1.96
Role of nitric oxide in maintaining vascular integrity in endotoxin-induced acute intestinal damage in the rat. Br J Pharmacol (1990) 1.94
Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. J Anat (1999) 1.94
Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol (1990) 1.93
Effects of NG-nitro-L-arginine methyl ester on vasodilator responses to acetylcholine, 5'-N-ethylcarboxamidoadenosine or salbutamol in conscious rats. Br J Pharmacol (1991) 1.90
Regional and cardiac haemodynamic responses to glyceryl trinitrate, acetylcholine, bradykinin and endothelin-1 in conscious rats: effects of NG-nitro-L-arginine methyl ester. Br J Pharmacol (1990) 1.77
Nitric oxide and lung disease. Thorax (1993) 1.77
L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest (1991) 1.73
Chronic nitric oxide inhibition model six years on. Hypertension (1998) 1.72
Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol (1996) 1.68
Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: antinociceptive and cardiovascular effects. Br J Pharmacol (1993) 1.66
Tumor necrosis factor alpha activates soluble guanylate cyclase in bovine glomerular mesangial cells via an L-arginine-dependent mechanism. J Exp Med (1990) 1.62
Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest (1998) 1.62
Endothelium-dependent contractions in hypertension. Br J Pharmacol (2005) 1.59
Immediate release of a nitric oxide-like factor from bovine aortic endothelial cells by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A (1990) 1.54
Nitric oxide signaling and the regulation of myocardial function. J Mol Cell Cardiol (2008) 1.50
Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest (2003) 1.43
St Cyres lecture. Endothelium in control. Br Heart J (1991) 1.43
Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci U S A (1999) 1.41
Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A (1992) 1.39
Endothelium-dependent vascular responses. Mediators and mechanisms. J Clin Invest (1989) 1.36
Characterization of the L-arginine:nitric oxide pathway in human platelets. Br J Pharmacol (1990) 1.36
Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest (1995) 1.32
Effects of inhibition of nitric oxide formation on basal vasomotion and endothelium-dependent responses of the coronary arteries in awake dogs. J Clin Invest (1991) 1.32
Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol (1994) 1.28
Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease. Free Radic Biol Med (2010) 1.25
The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats. Br J Pharmacol (1991) 1.23
Particulate air pollution and vascular reactivity: the bus stop study. Int Arch Occup Environ Health (2007) 1.23
The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J (2010) 1.21
Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci U S A (1994) 1.21
Role of nitric oxide in renal medullary oxygenation. Studies in isolated and intact rat kidneys. J Clin Invest (1991) 1.20
Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest (1992) 1.18
Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov (2015) 1.18
NG-methyl-L-arginine causes endothelium-dependent contraction and inhibition of cyclic GMP formation in artery and vein. Proc Natl Acad Sci U S A (1990) 1.17
Endogenous nitric oxide and sensory neuropeptides interact in the modulation of the rat gastric microcirculation. Br J Pharmacol (1992) 1.17
L-arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. J Clin Invest (1991) 1.15
eNOS activation and NO function: pregnancy adaptive programming of capacitative entry responses alters nitric oxide (NO) output in vascular endothelium--new insights into eNOS regulation through adaptive cell signaling. J Endocrinol (2011) 1.15
Modulation of angiotensin II-induced vasoconstriction by endothelium-derived relaxing factor in the isolated microperfused rabbit afferent arteriole. J Clin Invest (1991) 1.15
Participation of endothelium-derived nitric oxide but not prostacyclin in the gastric mucosal hyperaemia due to acid back-diffusion. Br J Pharmacol (1992) 1.15
Thirteenth Gaddum Memorial Lecture. Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: integrity in the balance. Br J Pharmacol (1993) 1.14
Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol (1992) 1.13
Increased endothelial nitric-oxide synthase expression reduces hypertension and hyperinsulinemia in fructose-treated rats. J Pharmacol Exp Ther (2008) 1.13
Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol (1994) 1.13
Nitric oxide is the mediator of ATP-induced dilatation of the rabbit hepatic arterial vascular bed. Br J Pharmacol (1991) 1.12
Effect of heme arginate administration on blood pressure in spontaneously hypertensive rats. J Clin Invest (1990) 1.11
Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol (1996) 1.11
The influence of atropine and atenolol on the cardiac haemodynamic effects of NG-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br J Pharmacol (1992) 1.11
Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci (2006) 1.10
Nitric oxide-dependent release of vasodilator quantities of calcitonin gene-related peptide from capsaicin-sensitive nerves in rabbit skin. Br J Pharmacol (1994) 1.08
Does nitric oxide mediate the increases in cerebral blood flow elicited by hypercapnia? Proc Natl Acad Sci U S A (1992) 1.08
Endogenous nitric oxide as a modulator of rabbit skeletal muscle microcirculation in vivo. Br J Pharmacol (1990) 1.08
Endothelium-dependent contractions: when a good guy turns bad! J Physiol (2008) 1.08
Effects of NG-nitro-L-arginine and L-arginine on regional cerebral blood flow in the cat. J Physiol (1992) 1.07
Involvement of nitric oxide in the endothelium-dependent relaxation induced by hydrogen peroxide in the rabbit aorta. Br J Pharmacol (1993) 1.07
Differential effects of L-arginine on the inhibition by NG-nitro-L-arginine methyl ester of basal and agonist-stimulated EDRF activity. Br J Pharmacol (1991) 1.06
Direct actions of nitric oxide on rat neurohypophysial K+ channels. J Physiol (1999) 1.05
Effect of inhibitors of nitric oxide release and action on vascular tone in isolated lungs of pig, sheep, dog and man. J Physiol (1994) 1.05
Tetrahydrobiopterin in cardiovascular health and disease. Antioxid Redox Signal (2014) 1.04
Constitutive nitric oxide synthase activation is a significant route for nitroglycerin-mediated vasodilation. Proc Natl Acad Sci U S A (2008) 1.04
Developmental changes in endothelium-dependent pulmonary vasodilatation in pigs. Br J Pharmacol (1992) 1.03
The involvement of endothelium-derived relaxing factor in the regulation of renal cortical blood flow in the rat. Br J Pharmacol (1991) 1.02
Coronary vasoconstriction in the conscious rabbit following intravenous infusion of L-NG-nitro-arginine. Br J Pharmacol (1991) 1.02
Neuronal nitric oxide synthase and human vascular regulation. Trends Cardiovasc Med (2009) 1.01
Effects of NG-nitro-L-arginine methyl ester or indomethacin on differential regional and cardiac haemodynamic actions of arginine vasopressin and lysine vasopressin in conscious rats. Br J Pharmacol (1991) 0.99
Inhibitory role of endothelium-derived relaxing factor in rat and human pulmonary arteries. Br J Pharmacol (1990) 0.99
Cardiovascular consequences when nitric oxide and lipid signaling converge. Circ Res (2009) 0.98
The role of the L-arginine-nitric oxide pathway in relaxation of the opossum lower oesophageal sphincter. Br J Pharmacol (1991) 0.98
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 40.02
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A (1987) 14.22
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77
The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol (1984) 6.74
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30
The nature of endothelium-derived vascular relaxant factor. Nature (1984) 5.53
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 3.44
The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25
Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol (1988) 3.24
Quantitative and kinetic characterization of nitric oxide and EDRF released from cultured endothelial cells. Biochem Biophys Res Commun (1988) 2.86
Preparation and characterization of Ng-mono-, di- and trimethylated arginines. Acta Biochim Biophys Acad Sci Hung (1977) 2.62
Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. Br J Pharmacol (1988) 2.32
Vasodilatation by acetylcholine is endothelium-dependent: a study by sonomicrometry in canine femoral artery in vivo. J Physiol (1983) 1.81
Flow-dependent, endothelium-mediated dilation of epicardial coronary arteries in conscious dogs: effects of cyclooxygenase inhibition. J Cardiovasc Pharmacol (1985) 1.62
Decreased endothelium-dependent relaxation in New Zealand genetic hypertensive rats. J Hypertens (1984) 1.46
Chronic treatment with SCH 23390, a selective dopamine D-1 receptor antagonist, decreases dopamine metabolism in rat caudate nucleus. Eur J Pharmacol (1988) 1.45
Laser-induced endothelial damage inhibits endothelium-dependent relaxation in the cerebral microcirculation of the mouse. Circ Res (1987) 1.23
Endothelium dependent vascular relaxation by arginine containing polypeptides. Biochem Biophys Res Commun (1986) 1.23
Endothelium-dependent responses in carotid and renal arteries of normotensive and hypertensive rats. Hypertension (1988) 1.19
Vascular relaxation and cGMP in hypertension. Am J Physiol (1988) 1.18
Inhibition of vasodilatation by methylene blue in large and small arteries of the dog hindlimb in vivo. Clin Exp Pharmacol Physiol (1988) 1.13
Gossypol attenuates selectively the blood pressure lowering effect of endothelium-dependent vasodilators in the rabbit in vivo. Eur J Pharmacol (1988) 1.10
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A (1989) 7.79
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol (1989) 6.87
Nitric oxide synthases in mammals. Biochem J (1994) 6.50
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30
Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20
Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA (2001) 6.02
Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol (1990) 5.87
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14
The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23
Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19
Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol (1988) 4.16
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98
A randomized trial of care in a hospital medical unit especially designed to improve the functional outcomes of acutely ill older patients. N Engl J Med (1995) 3.77
Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons. Ann Intern Med (1997) 3.76
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74
Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett (1991) 3.43
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29
Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25
Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A (1991) 3.22
Does delirium contribute to poor hospital outcomes? A three-site epidemiologic study. J Gen Intern Med (1998) 3.21
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res (1992) 3.15
Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun (1990) 3.14
Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 3.10
An improved method for washing of human platelets with prostacyclin. Thromb Res (1983) 3.07
Control of regional blood flow by endothelium-derived nitric oxide. Hypertension (1990) 2.93
Functional status before hospitalization in acutely ill older adults: validity and clinical importance of retrospective reports. J Am Geriatr Soc (2000) 2.92
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun (1991) 2.79
Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun (1989) 2.73
Nitric oxide synthase activities in human myocardium. Lancet (1993) 2.72
Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A (1994) 2.70
Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol (1989) 2.68
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67
Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis (1992) 2.63
Chemokinetic activity of arachidonic and lipoxygenase products on leuocyctes of different species. Prostaglandins (1980) 2.59
Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis (1989) 2.58
NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol (1989) 2.53
Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor. Lancet (1994) 2.53
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51
Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide. Biochem J (1992) 2.51
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet (1992) 2.44
Measuring prognosis and case mix in hospitalized elders. The importance of functional status. J Gen Intern Med (1997) 2.42
S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol (1992) 2.39
The role of TH1 and TH2 cells in a rodent malaria infection. Science (1993) 2.38
Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol (1992) 2.32
Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. Br J Pharmacol (1988) 2.32
Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun (1990) 2.31
Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun (1990) 2.31
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Nitric oxide synthase activity in human gynecological cancer. Cancer Res (1994) 2.27
Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol (1999) 2.26
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (1980) 2.24